The progress in the research of antiplatelet agents (1995-2017)

被引：13

作者：

Benimana, Oscar ^{[1
]}

Zhao, Lulu ^{[1
]}

Kong, Yi ^{[1
]}

Li, Zhiyu ^{[1
]}

Xie, Zhouling ^{[1
]}

机构：

[1] China Pharmaceut Univ, Jiangsu Key Lab Drug Design & Optimizat, 24 Tongjiaxiang, Nanjing 210009, Jiangsu, Peoples R China

来源：

FUTURE MEDICINAL CHEMISTRY | 2017年 / 9卷 / 10期

基金：

中国国家自然科学基金;

关键词：

antagonists; antiplatelet agents; antithrombus; bleeding risk; development; platelet activation; platelet surface receptor; ACUTE CORONARY SYNDROMES; ACTIVATED RECEPTOR 4; EP3; RECEPTOR; DUAL ANTICOAGULANT; P2Y(1) ANTAGONISTS; ALPHA-BINDING; IN-VITRO; POTENT; DISCOVERY; CLOPIDOGREL;

D O I：

10.4155/fmc-2017-0001

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Antiplatelet therapy displays a critical role in the treatment and prevention of antithrombotic disorders. Many new antiplatelet agents have been developed following the emergence of various clinical limitations of classical antiplatelet drugs. This review covers mainly the recent advances in the development of P2Y(12) antagonists and GPIIb/IIIa antagonists. Meanwhile, it summarizes promising approaches to new platelet surface receptors such as prostanoid EP3 receptor, thromboxane A(2) prostanoid receptor, protease-activated receptors, GPIb-IX-V receptor and P-selectin. In addition, PI3K(beta), a critical protein at the inside signaling pathway of platelet activation is also mentioned as an important antiplatelet target. Moreover, the development of respective drug candidates is discussed in detail.

引用

页码：1087 / 1110

页数：24

共 85 条

[1] Use of antiplatelet agents in sepsis: A glimpse into the future [J].

Akinosoglou, Karolina ;

Alexopoulos, Dimitrios .

THROMBOSIS RESEARCH, 2014, 133 (02) :131-138

[2]

Alan D.M., 2010, NAT REV DRUG DISCOV, V9, P154

[3] Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283 [J].

Bach, Peter ;

Antonsson, Thomas ;

Bylund, Ruth ;

Bjorkman, Jan-Arne ;

Osterlund, Krister ;

Giordanetto, Fabrizio ;

van Giezen, J. J. J. ;

Andersen, Soren M. ;

Zachrisson, Helen ;

Zetterberg, Fredrik .

JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (17) :7015-7024

[4] Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor [J].

Bach, Peter ;

Bostrom, Jonas ;

Brickmann, Kay ;

van Giezen, J. J. J. ;

Groneberg, Robert D. ;

Harvey, Darren M. ;

O'Sullivan, Michael ;

Zetterberg, Fredrik .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 65 :360-375

[5] Cyclopentane-1,3-dione: A Novel Isostere for the Carboxylic Acid Functional Group. Application to tie Design of Potent Thromboxane (A2) Receptor Antagonists [J].

Ballatore, Carlo ;

Soper, James H. ;

Piscitelli, Francesco ;

James, Michael ;

Huang, Longchuan ;

Atasoylu, Onur ;

Huryn, Donna M. ;

Trojanowski, John Q. ;

Lee, Virginia M. -Y. ;

Brunden, Kurt R. ;

Smith, Amos B., III .

JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (19) :6969-6983

[6] Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor [J].

Bartunek, Jozef ;

Barbato, Emanuele ;

Heyndrickx, Guy ;

Vanderheyden, Marc ;

Wijns, William ;

Holz, Josefin-Beate .

JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2013, 6 (03) :355-363

[7] Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) [J].

Bertrand, ME ;

Rupprecht, HJ ;

Urban, P ;

Gershlick, AH .

CIRCULATION, 2000, 102 (06) :624-629

[8] Management of thrombotic thrombocytopenic purpura: current perspectives [J].

Blombery, Piers ;

Scully, Marie .

JOURNAL OF BLOOD MEDICINE, 2014, 5 :15-23

[9] N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist [J].

Boldron, Christophe ;

Besse, Angelina ;

Bordes, Marie-Francoise ;

Tissandie, Stephanie ;

Yvon, Xavier ;

Gau, Benjamin ;

Badorc, Alain ;

Rousseaux, Tristan ;

Barre, Guillaume ;

Meneyrol, Jerome ;

Zech, Gernot ;

Nazare, Marc ;

Fossey, Valerie ;

Pflieger, Anne-Marie ;

Bonnet-Lignon, Sandrine ;

Millet, Laurence ;

Briot, Christophe ;

Dol, Frederique ;

Herault, Jean-Pascal ;

Savi, Pierre ;

Lassalle, Gilbert ;

Delesque, Nathalie ;

Herbert, Jean-Marc ;

Bono, Francoise .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (17) :7293-7316

[10] Aspirin resistance may increase death risk in some patients with heart disease [J].

Bradbury, J .

LANCET, 2002, 359 (9312) :1128-1128

← 1 2 3 4 5 6 7 8 9 →